(QURE) uniQure N.V. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(QURE) uniQure N.V. Complete Analysis Pack
uniQure’s Gene Therapy Business Model, Made Clear
Unlock the full strategic blueprint behind uniQure N.V.’s business model. This concise Business Model Canvas breaks down how the company creates value, builds key partnerships, and monetizes its gene therapy pipeline. Ideal for investors, analysts, and strategists who want clear, actionable insight—get the full version to see every detail.
Partnerships
CSL Behring hemophilia B commercialization
CSL Behring is uniQure N.V.’s core commercialization partner for etranacogene dezaparvovec, sold as HEMGENIX. The one-dose therapy has a U.S. list price of $3.5 million and the CSL network supports global market access, payer execution, and post-launch delivery in hemophilia B.
HOPE-B clinical trial sites
Specialist hemophilia centers and investigators run the Phase III HOPE-B study, which enrolled 54 adults with severe or moderately severe hemophilia B. These sites handle patient enrollment, one-time dosing, and long-term follow-up, generating the pivotal efficacy and safety data that support uniQure N.V.'s gene therapy strategy.
CDMO and GMP manufacturing partners
uniQure N.V. relies on in-house GMP capacity and CDMO partners to make and scale AAV vector supply for clinical and future commercial use. In gene therapy, batch release and QC are strict gates, so partner reliability directly affects speed, cost, and launch readiness.
FDA and EMA regulatory bodies
FDA and EMA are core partners for uniQure N.V.'s gene therapy pipeline: the company must clear 2 major regulators for trial starts, biologics review, and post-approval safety checks. This matters most in rare-disease programs like AMT-130, where small patient pools and long follow-up make regulatory alignment a make-or-break step.
2 key regulators: FDA and EMA
Needed for trial approval and review
Critical for rare-disease gene therapies
Academic neuroscience centers
Academic neuroscience centers are key partners for uniQure N.V. because they give access to rare-disease patients and disease expertise across AMT-130, AMT-210, AMT-260, AMT-161, and AMT-240. They also support translational science and biomarker work, which matters in a pipeline built around 5 neuro programs.
- Rare-patient access
- Biomarker and translational support
- Clinical expertise for 5 programs
These hospital links help speed study enrollment and sharpen proof-of-concept data in ALS, Huntington's disease, and other CNS disorders.
uniQure’s Key Partnerships Power Hemgenix and Rare-Disease Growth
uniQure N.V.’s key partnerships center on CSL Behring for HEMGENIX commercialization, with a $3.5 million U.S. list price, plus FDA/EMA ties for trial and review. Hospital and academic centers also matter for its 5 neuro programs, including HOPE-B’s 54-patient dataset and long follow-up in rare diseases.
| Partner | Role | Key data |
|---|---|---|
| CSL Behring | Commercialization | $3.5 million list price |
| FDA/EMA | Regulation | 2 major regulators |
| HOPE-B sites | Clinical delivery | 54 patients |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for uniQure N.V. mapping its gene therapy platform, partners, customers, and value creation.
Customizable Excel Spreadsheet
Quickly clarifies uniQure’s business model in one editable view, saving time and reducing analysis friction.
Reference Sources
Provides a credible source trail for uniQure N.V. that supports faster due diligence and better decision-making.
Activities
AAV gene therapy discovery
uniQure designs and engineers AAV gene therapy candidates, with 2 core program paths: liver-targeted and CNS-targeted. This discovery engine feeds the company’s pipeline, including advanced programs like AMT-061 for hemophilia B and AMT-130 for Huntington’s disease.
Clinical development across multiple phases
uniQure runs multi-phase clinical development in hemophilia B and neurology, with the pivotal 54-patient HOPE-B Phase III program for etranacogene dezaparvovec. Earlier-stage work includes Phase I/II studies AMT-130 in Huntington’s disease and AMT-060 in hemophilia B.
GMP vector manufacturing
GMP vector manufacturing is a core uniQure N.V. activity, because its AAV gene therapies depend on tightly controlled viral vector production. The company must keep each batch within strict potency, purity, and consistency specs, while scaling supply for clinical use and future commercialization; uniQure’s AMT-130 program has enrolled 29 patients, so reliable output matters now.
Regulatory submissions and safety monitoring
uniQure prepares IND, BLA, and related filings, then runs long-term follow-up and adverse-event tracking to meet gene therapy rules. For one-time therapies, FDA-style safety monitoring can run up to 15 years, so this work protects approval timing and post-market access.
- IND and BLA package prep
- 15-year safety follow-up window
- Ongoing adverse-event reporting
Partner and lifecycle management
uniQure N.V. manages its CSL Behring tie-up and other development partners to keep programs on track, while it runs evidence generation, medical affairs, and lifecycle plans for assets like AMT-130. This matters because post-approval value depends on clean data, payer proof, and a steady partner handoff.
- One CSL Behring core partnership
- Supports post-approval value retention
- Builds evidence for regulators and payers
uniQure’s Gene Therapy Push Advances with AMT-130 and CSL Behring
uniQure N.V. centers its key activities on AAV gene therapy R&D, clinical development, and GMP vector manufacturing for liver and CNS programs. Its lead work includes AMT-130 in Huntington’s disease with 29 patients enrolled, plus long-cycle regulatory filings, 15-year safety follow-up, and CSL Behring partnership management.
| Key activity | Latest data |
|---|---|
| AMT-130 enrollment | 29 patients |
| Safety follow-up | Up to 15 years |
| Core partnership | 1 CSL Behring tie-up |
Full Version Awaits
Business Model Canvas
The uniQure N.V. Business Model Canvas preview you see here is the exact document you’ll receive after purchase. It is not a sample or mockup, but a real view of the final file. Once your order is complete, you’ll get the same professionally formatted document, ready to use, edit, or present. What you preview is what you receive—no surprises.
Resources
Proprietary AAV platform
uniQure N.V.'s proprietary AAV platform is its core asset: it enables one-time delivery of therapeutic genes and underpins the full pipeline, from hemophilia programs to neurology. In FY2025, this platform remained the base of its R&D spend and value creation, with AAV know-how and vector design driving the Company’s lead programs and partnerships.
Clinical pipeline assets
uniQure N.V. has 7 named clinical pipeline assets: AMT-061, AMT-130, AMT-060, AMT-210, AMT-260, AMT-161, and AMT-240. They span hemophilia, Huntington’s disease, Parkinson’s disease, epilepsy, ALS, and Alzheimer’s disease, so the breadth of this pipeline is a core strategic resource and a major source of future value.
Clinical and commercial data
Clinical and commercial data from HOPE-B and HEMGENIX sales are key assets for uniQure N.V.; HEMGENIX launched at a $3.5 million list price and gives real-world proof on uptake, payer access, and durability. That evidence helps support regulatory follow-up, reimbursement talks, and new partner deals while lowering development risk versus trial data alone.
Intellectual property portfolio
uniQure N.V.’s intellectual property portfolio protects its AAV vector design, manufacturing know-how, and gene-therapy constructs, which is vital in a capital-heavy business where one program can take years and large R&D spend before revenue. The patent base also strengthens licensing talks and gives uniQure more leverage in collaborations around AMT-130 and its broader platform.
- Protects vector and construct design
- Supports licensing value
- Hardens a high-capex biotech moat
Amsterdam headquarters and specialist teams
uniQure N.V. is headquartered in Amsterdam, Netherlands, and that site anchors its scientific, clinical, regulatory, and business teams. For rare-disease gene therapy, this specialist base matters because development needs tight coordination across one complex path: target validation, trial design, CMC, and regulator-facing work.
- Amsterdam is the operating hub.
- Specialist teams drive gene therapy work.
- Rare-disease programs need deep expertise.
uniQure’s AAV Platform Fuels FY2025 Pipeline Value
uniQure N.V.'s key resources are its AAV gene-therapy platform, seven named pipeline assets, and IP on vector design and manufacturing. In FY2025, these assets anchored R&D and kept AMT-130 and hemophilia programs at the center of value creation.
| Key resource | FY2025 fact |
|---|---|
| AAV platform | Core delivery engine |
| Named assets | 7 clinical programs |
| Commercial proof | HEMGENIX at $3.5m list price |
Value Propositions
One-time gene therapy treatment
uniQure N.V. positions its gene therapies as one-time infusions, so patients can avoid years of chronic dosing and the costs tied to repeat treatment. Its approved hemophilia B therapy, HEMGENIX, is a single-administration product for adults with severe disease, where even one infusion can replace frequent factor replacement.
Durable hemophilia B benefit
uniQure N.V.'s etranacogene dezaparvovec is built to deliver sustained factor IX expression in hemophilia B, with HOPE-B showing mean factor IX activity of 36.9% at 24 months and a 64% annualized bleed-rate reduction from baseline. One infusion aims to cut bleeds long term and reduce dependence on lifelong replacement therapy, a major unmet need.
Advanced CNS gene therapy pipeline
uniQure N.V.’s advanced CNS gene therapy pipeline targets Huntington’s disease, Parkinson’s disease, epilepsy, ALS, and Alzheimer’s disease, all areas with few disease-modifying treatments. The platform broadens the Company Name’s gene therapy reach beyond hematology and builds on a 2025 pipeline of 5 major CNS programs, with a lead asset in Huntington’s disease.
Severe rare-disease focus
uniQure targets severe rare diseases with high unmet need, where even small efficacy gains can matter. In 2025, its lead Huntington’s disease program, AMT-130, reported up to 75% slowing in cUHDRS decline at 36 months in the high-dose group, supporting both clinical and pricing power.
- Focuses on debilitating, low-option diseases
- Can justify premium orphan-drug economics
- Clinical upside can be large from small trials
Potential long-duration response
uniQure N.V.’s value prop is a one-time dose that aims to deliver a long-lasting effect, so patients may avoid repeated treatment cycles and frequent clinic trips. In gene therapy, that long-duration benefit is the key economic driver: 1 dose can replace years of ongoing infusion needs, which can lower burden for patients and payers.
- 1 dose, long-lasting effect
- Fewer clinic visits
- Lower ongoing infusion need
uniQure’s One-Dose Gene Therapies Aim to Rewrite Rare Disease Care
uniQure N.V. offers one-time gene therapies for severe rare diseases, aiming to replace years of chronic dosing, repeat infusions, and clinic visits. Its lead assets include HEMGENIX for hemophilia B and AMT-130 for Huntington’s disease, which in 2025 showed up to 75% slowing in cUHDRS decline at 36 months in the high-dose group.
| Value driver | Data |
|---|---|
| HEMGENIX | Single-dose hemophilia B therapy |
| AMT-130 | Up to 75% cUHDRS slowing |
Customer Relationships
Specialist-led high-touch support
uniQure N.V. uses specialist physicians and treatment centers to manage patients, so the relationship is highly consultative. Gene therapy needs individualized education and coordination, especially around dosing, monitoring, and long follow-up, which fits a high-touch model for complex care.
Clinical investigator collaboration
uniQure N.V. works closely with clinical investigators in trials and follow-up studies to recruit patients, run protocols, and keep data clean. That matters most in rare diseases: its AMT-130 Huntington’s program has enrolled 29 patients, so every site and investigator has a big impact on execution and readout quality.
Long-term safety follow-up
Gene therapy is not a one-and-done sale: uniQure N.V. follows patients for years after dosing to track durability, outcomes, and safety signals. For many gene therapy programs, long-term follow-up can run up to 15 years, so this is a durable relationship built on ongoing data, not a single treatment visit.
Reimbursement and access support
High-cost gene therapies can top $3 million per patient, so uniQure N.V. and its partner must support payer coverage, prior-authorization, and treatment-pathway talks to reduce delays at the point of care. This makes access smoother for hospitals and patients, and it is central to moving one-time therapies from trial data to real-world use.
- Supports payer coverage talks
- Guides access and care pathways
- Reduces treatment-day friction
Medical education and evidence sharing
uniQure N.V. uses peer-reviewed data, conference talks, and scientific publications to teach clinicians how gene therapy works and why it is safe and durable. This matters because only 1 approved medicine in the class exists today, so trust and real-world evidence are key to adoption in specialized treatment centers.
- Builds clinician trust with published data
- Supports uptake in expert centers
- Uses conference and journal evidence
High-Touch Relationships Drive uniQure’s Rare-Disease Growth
uniQure N.V. keeps customer ties high-touch: expert physicians, treatment centers, and trial sites guide rare-disease care, while long-term follow-up tracks safety and durability for years. Its AMT-130 Huntington’s program had 29 patients enrolled, so clinician and investigator relationships directly affect data quality, access, and adoption.
| Key relationship | Data point |
|---|---|
| AMT-130 enrollment | 29 patients |
| Follow-up horizon | Up to 15 years |
Channels
Specialty treatment centers
Specialty treatment centers are uniQure N.V.’s main gateway to patients: hemophilia and neurology sites diagnose, refer, and deliver advanced gene therapies. In the U.S., about 140 federally funded hemophilia treatment centers anchor care, so access depends on these centers’ ability to identify eligible patients and manage infusion and follow-up.
CSL Behring commercial network
HEMGENIX reaches patients through CSL Behring’s global commercial network, which gives uniQure N.V. broad market access and launch scale across major hemophilia B markets. CSL Behring is the key channel for this approved one-time gene therapy, supporting treatment delivery in a class with about 19,000 hemophilia B patients in the U.S. and Europe combined.
Clinical trial referral networks
Clinical trial referral networks are critical for uniQure N.V. because enrollment in rare-disease studies still depends on physician referrals and specialist awareness. The channel supports six pipeline programs, including AMT-130, AMT-060, AMT-210, AMT-260, AMT-161, and AMT-240, and helps locate the small patient pools needed for timely enrollment.
Scientific congresses and publications
Scientific congresses and peer-reviewed journals are uniQure N.V.'s key proof points for new gene therapy data, helping reach clinicians, researchers, and payers. In 2025/2026, this channel matters most for high-stakes evidence on durability, safety, and patient outcomes, where one strong dataset can shape adoption.
- Reaches clinicians, researchers, payers
- Supports gene therapy evidence
- Builds trust with peer review
Corporate and medical information channels
uniQure N.V. uses its website and medical affairs contacts to give direct access to investors, investigators, physicians, and patients, while also posting trial updates and corporate disclosures. In 2025, its public filings and study news were the main source for pipeline and financing updates.
- Direct access via website and medical affairs
- Serves investors, investigators, physicians, patients
- Shares trial updates and disclosures
uniQure’s key care channels drive access in 2025/2026
uniQure N.V. reaches patients mainly through specialty treatment centers, CSL Behring’s HEMGENIX network, and rare-disease referral paths. In 2025/2026, these channels matter most for its six programs and for the about 140 U.S. hemophilia treatment centers that steer diagnosis and infusion care.
| Channel | Role | Key data |
|---|---|---|
| Specialty centers | Dx, refer, treat | 140 U.S. HTC |
| CSL Behring | HEMGENIX reach | 19,000 pts |
Customer Segments
Severe hemophilia B patients
Severe hemophilia B patients are HEMGENIX’s lead commercial group: they have factor IX activity under 1% and usually need lifelong, durable factor IX replacement, often under hemophilia specialists. Hemophilia B affects about 1 in 25,000 male births, and severe cases are the smallest but highest-burden segment, making them the clearest fit for a one-time gene therapy.
Huntington’s disease patients
AMT-130 targets Huntington’s disease patients, a small but high-need group that depends on specialist neurology care. Huntington’s affects about 41,000 people in the United States and roughly 300,000 worldwide, with no cure and a median age at onset near 35 to 44 years.
Because symptoms progress over 10 to 20 years and drive costly motor, cognitive, and psychiatric care needs, uniQure’s customer segment is concentrated in tertiary centers that manage complex neurodegenerative disease.
Other rare neurological disease patients
uniQure N.V. targets small but high-need patient groups in Parkinson’s disease, temporal lobe epilepsy, ALS, and autosomal dominant Alzheimer’s disease. These CNS markets are clinically important: Parkinson’s affects about 10 million people worldwide, epilepsy about 50 million, ALS about 300,000, and Alzheimer’s about 55 million, so even narrow subsets can support meaningful gene-therapy value.
Specialty physicians and hospitals
Hemophilia treatment centers and neuroscience hospitals are the main gatekeepers for uniQure N.V.’s gene therapies; they shape adoption, referrals, and infusion use. In the U.S., about 140 federally funded hemophilia treatment centers serve roughly 30,000 people with hemophilia, while high-volume neuroscience hospitals handle the complex monitoring needed for CNS gene therapy.
- Key decision-makers for adoption and referral
- Need deep gene-therapy expertise
- Support administration and long-term follow-up
Payers and health systems
Public and private payers are the gatekeepers for uniQure N.V.'s high-value gene therapies, because reimbursement decisions can make or break adoption. Health systems also shape access pathways and site readiness; in the U.S., 2025 Medicare covers about 66 million people, so hospital and payer approval is central to commercialization.
- Reimbursement drives patient access
- Health systems set site readiness
- Approval supports commercialization
uniQure’s rare-disease market: small patient pools, big gene-therapy pricing power
uniQure N.V. sells to rare-disease patients with severe unmet need, but access is decided by hemophilia centers, neuroscience hospitals, and payers. Its core segments are severe hemophilia B and specialist CNS groups like Huntington’s disease, where even small patient pools can support one-time gene-therapy pricing.
| Segment | 2025 data |
|---|---|
| Medicare | 66M covered |
| HTCs | ~140 U.S. |
Cost Structure
R and D spending
R and D spending is uniQure N.V.’s largest cost line, and its latest filings show it stays above the rest of operating spend because gene therapy needs discovery, preclinical work, and program advancement at the same time. This is a sustained cash drain: one late-stage asset can require years of funding before any product revenue arrives.
Clinical trial costs
Clinical trial costs are a major uniQure N.V. expense: Phase I/II and Phase III studies can run for years, and rare-disease programs need small, global patient pools, specialty shipping, and tight monitoring. Costs stack up in enrollment, site fees, data management, and safety oversight, so per-patient spend stays high even when trial sizes are small.
Manufacturing and quality control
Vector production, testing, and batch release are among uniQure N.V.’s highest-cost steps, because each GMP run needs clean-room capacity, analytics, and strict release controls. Commercial gene therapy supply is especially capital intensive, with site build-outs and validation often running into tens of millions of dollars before scale is reached.
Regulatory and legal expenses
Regulatory and legal expenses stay high for uniQure N.V. because every filing, inspection, IP filing, and compliance review must pass U.S., EU, and local rules. In global gene therapy development, these costs are not optional; they protect approval rights and defend the platform, even when no separate FY2025 line item is disclosed.
- Filings and inspections add recurring cash costs.
- IP protection helps guard market exclusivity.
- Multi-country trials raise jurisdiction-specific spend.
General and administrative overhead
General and administrative overhead is a fixed cost base for uniQure N.V.: headquarters, finance, HR, legal, and partner management must run even when R&D spend shifts. HEMGENIX commercial support adds extra operating load, so the lean structure still needs strong back-office coverage to support one approved product and the late-stage pipeline.
- Fixed HQ, finance, HR, legal costs
- HEMGENIX support lifts overhead
- Small team still needs scale support
uniQure’s 2025 Costs Stay Heavy on R&D, Trials, and Manufacturing
uniQure N.V.’s cost base is still driven by R and D, clinical trials, and GMP vector production, with 2025 filings showing heavy spend on late-stage gene therapy work and HEMGENIX support. Fixed G&A stays meaningful too, since the platform needs finance, legal, IP, and compliance work even with limited product revenue.
| Cost driver | FY2025 focus |
|---|---|
| R and D | Largest cash use |
| Clinical trials | Phase I/II and III |
| Manufacturing | GMP vector release |
Revenue Streams
HEMGENIX royalties
HEMGENIX royalties are uniQure N.V.'s main post-approval revenue stream from etranacogene dezaparvovec sales under its CSL Behring deal. In 2025, royalty income stayed tied to product uptake, so each added patient can lift high-margin revenue without adding much cost.
Milestone payments
uniQure N.V. can earn milestone payments when partnered programs hit development, regulatory, or commercial targets, and these deals are common in biotech. That cash is non-dilutive, so it can help fund ongoing R&D without issuing more shares.
Upfront and license fees
uniQure N.V. can earn upfront and license fees by partnering its AAV gene-therapy platform and IP, turning science into non-dilutive cash; that matters because the Company still depends on external funding, so every partner payment lowers pressure on equity raises and supports R&D without adding dilution.
Future product sales
As of FY2025, uniQure N.V. still had no approved commercial product, so product sales were not a revenue driver. If AMT-130 in Huntington’s disease or hemophilia gene therapies win approval, direct sales could become material and turn this into the group’s long-term growth stream.
- FY2025: no product sales yet
- Hemophilia and neurology are key future markets
- Approval would make sales material
Research collaboration revenue
uniQure N.V. can earn research collaboration revenue from sponsored work and shared development costs, which helps fund pipeline work before any product sales. This partner-backed model supports programs like its AAV gene therapy platform while lowering the company’s upfront R&D burden in FY2025.
Sponsored research and cost sharing
Funds pipeline execution early
Reduces net R&D cash burn
uniQure’s FY2025 Revenue Still Hinges on HEMGENIX Royalties
uniQure N.V.'s Revenue Streams in FY2025 were still led by HEMGENIX royalties from CSL Behring, with income rising only as treated patients increased. The Company also relied on milestone, license, and research collaboration fees, while product sales stayed at 0 because no uniQure N.V. therapy was yet approved for direct sale.
| Stream | FY2025 status |
|---|---|
| HEMGENIX royalties | Main cash source |
| Product sales | 0 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.